Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma

doi:10.4103/jcrt.JCRT_752_20

科研成果详情

题名	Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma
作者	Rafiee, Reihaneh 1; Razmara, Ehsan 2; Motavaf, Mahsa 3; Mohammadi, Majid Mossahebi-4; Khajehsharifi, Shima 5; Rouhollah, Fatemeh 1; Babashah, Sadegh 3
发表日期	2022-12
发表期刊	JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 影响因子和分区
语种	英语
原始文献类型	Article ; Journal Article
关键词	Biomarker circulating microRNAs colorectal cancer diagnosis
其他关键词	MICRORNA EXPRESSION ; FUNCTIONAL-ANALYSIS ; MIRNA EXPRESSION ; CANCER ; METASTASIS ; INVASION ; PCR
摘要	Background: Colorectal cancer (CRC) is one of the most common cancers worldwide. Although colonoscopy is considered as the Gold Standard technique to detect CRC, its application is invasive and cost incurred. Thus, noninvasive or minimally invasive approaches are of utmost importance. The aberrant expression of some microRNAs (miRNAs, miRs) has been suggested in association with CRC pathogenesis. This study aimed to validate if circulating serum miR-1229 and miR-1246 are diagnostic biomarkers for CRC. Materials and Methods: Serum samples were isolated from 45 CRC patients and also 45 healthy controls (HC). The expression levels of circulating serum-derived miR-1229 and miR-1246 were evaluated by quantitative real-time polymerase chain reaction. Receiver operating characteristic (ROC) curves were constructed to evaluate the CRC diagnostic accuracy of selected miRNAs. Furthermore, the association of candidate miRNAs and clinicopathological characteristics were evaluated. Functional enrichment of the candidate miRNAs was applied using in silico tools. Results: The expression of miR-1229 and miR-1246 was significantly higher in CRC patients than HC (P < 0.0001) and also was found in association with lymph node metastasis (P < 0.05). We demonstrated a significant up-regulation of serum-derived miR-1246 in advanced tumor-node-metastasis stage III of CRC patients (P < 0.05). Areas under the ROC curve of miR-1229 and miR-1246 were 0.81 and 0.84, respectively (P < 0.0001). Conclusion: We confirmed the capability of circulating serum miR-1229 and miR-1246 as novel diagnostic biomarkers for CRC.
出版者	WOLTERS KLUWER MEDKNOW PUBLICATIONS
出版地	MUMBAI
ISSN	0973-1482
EISSN	1998-4138
卷号	18 期号:9 页码:S383-+
DOI	10.4103/jcrt.JCRT_752_20
页数	10
WOS类目	Oncology
WOS研究方向	Oncology
WOS记录号	WOS:000908442000039
收录类别	SCIE ; SCOPUS ; PUBMED
URL	查看原文
Pubmed记录号	36510992
Scopus记录号	2-s2.0-85143994695
通讯作者地址	[Rouhollah, Fatemeh]Department of Cellular and Molecular Sciences,Faculty of Advanced Sciences and Technology,Islamic Azad University,Tehran Medical Sciences,Tehran,Iran
scopus学科分类	Medicine (all)
引用统计
文献类型	期刊论文
条目标识符	https://kms.wmu.edu.cn/handle/3ETUA0LF/172276
专题	卓越中心_国际生长因子研究院药学院（分析测试中心）
通讯作者	Rouhollah, Fatemeh
作者单位	1.Department of Cellular and Molecular Sciences,Faculty of Advanced Sciences and Technology,Islamic Azad University,Tehran Medical Sciences,Wenzhou,China; 2.Department of Medical Genetics,Faculty of Medical Sciences,Tarbiat Modares University,Wenzhou,China; 3.Department of Molecular Genetics,Faculty of Biological Sciences,Tarbiat Modares University,Wenzhou,China; 4.International Collaborative Center on Growth Factor Research,School of Pharmaceutical Sciences,Wenzhou Medical University,Wenzhou,China; 5.Sarem Cell Research Center,Sarem Hospital,Tehran,Iran
推荐引用方式 GB/T 7714	Rafiee, Reihaneh,Razmara, Ehsan,Motavaf, Mahsa,et al. Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma[J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS,2022,18(9):S383-+.
APA	Rafiee, Reihaneh., Razmara, Ehsan., Motavaf, Mahsa., Mohammadi, Majid Mossahebi-., Khajehsharifi, Shima., ... & Babashah, Sadegh. (2022). Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 18(9), S383-+.
MLA	Rafiee, Reihaneh,et al."Circulating serum miR-1246 and miR-1229 as diagnostic biomarkers in colorectal carcinoma".JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 18.9(2022):S383-+.